164 related articles for article (PubMed ID: 31570201)
1. A Chronology for the Identification and Disclosure of Adverse Effects of Succinylcholine.
Huang L; Sang CN; Desai MS
J Anesth Hist; 2019 Jul; 5(3):65-84. PubMed ID: 31570201
[TBL] [Abstract][Full Text] [Related]
2. [Happy birthday succinylcholine!].
Plaud B
Ann Fr Anesth Reanim; 2012 Oct; 31(10):770-2. PubMed ID: 23021935
[No Abstract] [Full Text] [Related]
3. The place of suxamethonium in pediatric anesthesia.
Rawicz M; Brandom BW; Wolf A
Paediatr Anaesth; 2009 Jun; 19(6):561-70. PubMed ID: 19645973
[TBL] [Abstract][Full Text] [Related]
4. Beyond Ether and Chloroform-A Major Breakthrough With Halothane.
Huang L; Sang CN; Desai MS
J Anesth Hist; 2017 Jul; 3(3):87-102. PubMed ID: 28842156
[TBL] [Abstract][Full Text] [Related]
5. PharmGKB summary: succinylcholine pathway, pharmacokinetics/pharmacodynamics.
Alvarellos ML; McDonagh EM; Patel S; McLeod HL; Altman RB; Klein TE
Pharmacogenet Genomics; 2015 Dec; 25(12):622-30. PubMed ID: 26398623
[No Abstract] [Full Text] [Related]
6. Aspects of depolarizing neuromuscular blockers: decamethonium and suxamethonium.
Brown TC
Paediatr Anaesth; 2013 Sep; 23(9):868-70. PubMed ID: 23398375
[No Abstract] [Full Text] [Related]
7. [Early achievements of the Danish pharmaceutical industry--8. Lundbeck].
Grevsen JV; Kirkegaard H; Kruse E; Kruse PR
Theriaca; 2016; (43):9-61. PubMed ID: 27491172
[TBL] [Abstract][Full Text] [Related]
8. Adverse effects of depolarising neuromuscular blocking agents. Incidence, prevention and management.
Book WJ; Abel M; Eisenkraft JB
Drug Saf; 1994 May; 10(5):331-49. PubMed ID: 8037887
[TBL] [Abstract][Full Text] [Related]
9. Succinylcholine-induced hyperkalemia and beyond. 1975.
Gronert GA
Anesthesiology; 2009 Dec; 111(6):1372-7. PubMed ID: 19934884
[No Abstract] [Full Text] [Related]
10. Unexpected complications during anesthesia.
Brown TC
Paediatr Anaesth; 2014 Mar; 24(3):335-8. PubMed ID: 23521362
[No Abstract] [Full Text] [Related]
11. Malignant hyperthermia: a case report in Thai Anesthesia Incidents Study (THAI Study).
Pulnitiporn A; Charuluxananan S; Inphum P; Kitsampanwong W
J Med Assoc Thai; 2005 Nov; 88 Suppl 7():S149-52. PubMed ID: 16862689
[TBL] [Abstract][Full Text] [Related]
12. Succinylcholine-induced hyperkalemia in acquired pathologic states: etiologic factors and molecular mechanisms.
Martyn JA; Richtsfeld M
Anesthesiology; 2006 Jan; 104(1):158-69. PubMed ID: 16394702
[TBL] [Abstract][Full Text] [Related]
13. Masseter muscle rigidity, elevated creatine kinase, and rhabdomyolysis following succinylcholine administration: a case report.
Fitzpatrick LR
AANA J; 2008 Oct; 76(5):349-54. PubMed ID: 18947162
[TBL] [Abstract][Full Text] [Related]
14. Fatal hyperkalemia following succinylcholine administration in a child on oral propranolol.
Ganigara A; Ravishankar C; Ramavakoda C; Nishtala M
Drug Metab Pers Ther; 2015 Mar; 30(1):69-71. PubMed ID: 25565545
[TBL] [Abstract][Full Text] [Related]
15. Variants of malignant hyperthermia. Special problems for the paediatric anaesthesiologist.
Rosenberg H; Shutack JG
Paediatr Anaesth; 1996; 6(2):87-93. PubMed ID: 8846290
[No Abstract] [Full Text] [Related]
16. Case of leptosuccin induced malignant hyperthermia in a patient with GIST of the rectum.
Natasa N; Snezana P; Nemanja Z; Zoran K; Durasić L
Acta Chir Iugosl; 2012; 59(2):121-3. PubMed ID: 23373371
[TBL] [Abstract][Full Text] [Related]
17. Malignant hyperthermia and muscular dystrophies.
Gurnaney H; Brown A; Litman RS
Anesth Analg; 2009 Oct; 109(4):1043-8. PubMed ID: 19762730
[TBL] [Abstract][Full Text] [Related]
18. Neuromuscular and mitochondrial disorders: what is relevant to the anaesthesiologist?
Driessen JJ
Curr Opin Anaesthesiol; 2008 Jun; 21(3):350-5. PubMed ID: 18458553
[TBL] [Abstract][Full Text] [Related]
19. Suxamethonium, masseter spasm and later malignant hyperthermia.
Ramirez JA; Cheetham ED; Laurence AS; Hopkins PM
Anaesthesia; 1998 Nov; 53(11):1111-6. PubMed ID: 10023282
[TBL] [Abstract][Full Text] [Related]
20. Caution for psychiatrists: malignant hyperthermia risks with the anesthetic agent succinylcholine (Suxamethonium) during electroconvulsive therapy.
Nakano M; Funayama M; Takata T; Wakisaka R; Koyama G; Koreki A; Ishida T; Uchida H; Mimura M
BMC Psychiatry; 2024 Jun; 24(1):411. PubMed ID: 38834964
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
